Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.

Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A

The Journal of clinical endocrinology and metabolism1 Nov 1996Cited by 160 (Europe PMC)

PMID8923830DOI10.1210/jcem.81.11.8923830PepBankPUB-08923830

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, serum PTH was unchanged in both rhIGF-I groups compared with placebo.
In plain wordsIn women with anorexia nervosa, serum PTH was unchanged in both rhIGF-I groups compared with placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeSerum PTH
Study
n = 23
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 or 30 micrograms/kg twice daily · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
Serum PTH and serum and urinary calcium were unchanged in both treatment groups compared to placebo levels.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383013
02HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, serum calcium was unchanged in both rhIGF-I groups compared with placebo.
In plain wordsIn women with anorexia nervosa, serum calcium was unchanged in both rhIGF-I groups compared with placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeSerum calcium
Study
n = 23
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 or 30 micrograms/kg twice daily · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
Serum PTH and serum and urinary calcium were unchanged in both treatment groups compared to placebo levels.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383014
03HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, urinary calcium was unchanged in both rhIGF-I groups compared with placebo.
In plain wordsIn women with anorexia nervosa, urinary calcium was unchanged in both rhIGF-I groups compared with placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeUrinary calcium
Study
n = 23
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 or 30 micrograms/kg twice daily · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
Serum PTH and serum and urinary calcium were unchanged in both treatment groups compared to placebo levels.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383015
04HumanRandomized controlled trialPharmacokinetics
In women with anorexia nervosa, IGF-I levels increased with high-dose rhIGF-I.
In plain wordsIn women with anorexia nervosa, IGF-I levels increased with high-dose rhIGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseIGF-I concentrations
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100 micrograms/kg twice daily · subcutaneous · 6 daysAs given in this study (human).
Measurements
serum IGF-I
203 ng/mL
baseline, +/- 93
serum IGF-I
673 ng/mL
100 micrograms/kg BID, +/- 268
p value for Serum IGF-I increase with rhIGF-I 100 micrograms/kg BID versus baseline
< 0.05 p value
Serum IGF-I increase with rhIGF-I 100 micrograms/kg BID versus baseline
Source sentences
Summary
IGF-I levels were relatively low at baseline compared to those in age-matched controls (203 +/- 93 vs. 262 +/- 84 ng/mL;P < 0.01) and increased to 673 +/- 268 ng/mL [P < 0.05; 100 micrograms/kg twice daily (BID)]
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383002
05HumanRandomized controlled trialPharmacokinetics
In women with anorexia nervosa, IGF-I levels increased with low-dose rhIGF-I.
In plain wordsIn women with anorexia nervosa, IGF-I levels increased with low-dose rhIGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseIGF-I concentrations
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
30 micrograms/kg twice daily · subcutaneous · 6 daysAs given in this study (human).
Measurements
serum IGF-I
203 ng/mL
baseline, +/- 93
serum IGF-I
545 ng/mL
30 micrograms/kg BID, +/- 255
p value for Serum IGF-I increase with rhIGF-I 30 micrograms/kg BID versus baseline
< 0.05 p value
Serum IGF-I increase with rhIGF-I 30 micrograms/kg BID versus baseline
Source sentences
Summary
IGF-I levels were relatively low at baseline compared to those in age-matched controls (203 +/- 93 vs. 262 +/- 84 ng/mL;P < 0.01) and increased to 673 +/- 268 ng/mL [P < 0.05; 100 micrograms/kg twice daily (BID)] and 545 +/- 255 ng/mL (P < 0.05; 30 micrograms/kg BID)
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383003
06HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, high-dose rhIGF-I significantly increased PICP.
In plain wordsIn women with anorexia nervosa, high-dose rhIGF-I increased PICP, a bone formation marker.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePICP
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 micrograms/kg BID · subcutaneous · 6 daysAs given in this study (human).
Measurements
PICP
147 ng/mL
100 micrograms/kg BID, before, +/- 33
PICP
303 ng/mL
100 micrograms/kg BID, after, +/- 187
p value for PICP increase with rhIGF-I 100 micrograms/kg BID versus pretreatment
< 0.05 p value
PICP increase with rhIGF-I 100 micrograms/kg BID versus pretreatment
Source sentences
Summary
During short term administration of rhIGF-I at a dose of 100 micrograms/kg BID, there was a significant (P < 0.05) increase in markers of bone formation, as assessed by both PICP (147 +/- 33 to 303 +/- 187 ng/mL) and OC (5.3 +/- 3.8 to 10.9 +/- 7.4 ng/mL).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383004
07HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, high-dose rhIGF-I significantly increased osteocalcin.
In plain wordsIn women with anorexia nervosa, high-dose rhIGF-I increased osteocalcin, a bone formation marker.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseOsteocalcin
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 micrograms/kg BID · subcutaneous · 6 daysAs given in this study (human).
Measurements
osteocalcin
5.3 ng/mL
100 micrograms/kg BID, before, +/- 3.8
osteocalcin
10.9 ng/mL
100 micrograms/kg BID, after, +/- 7.4
p value for Osteocalcin increase with rhIGF-I 100 micrograms/kg BID versus pretreatment
< 0.05 p value
Osteocalcin increase with rhIGF-I 100 micrograms/kg BID versus pretreatment
Source sentences
Summary
During short term administration of rhIGF-I at a dose of 100 micrograms/kg BID, there was a significant (P < 0.05) increase in markers of bone formation, as assessed by both PICP (147 +/- 33 to 303 +/- 187 ng/mL) and OC (5.3 +/- 3.8 to 10.9 +/- 7.4 ng/mL).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383005
08HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, high-dose rhIGF-I significantly increased pyridinoline.
In plain wordsIn women with anorexia nervosa, high-dose rhIGF-I increased pyridinoline, a bone resorption marker.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePyridinoline
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 micrograms/kg BID · subcutaneous · 6 daysAs given in this study (human).
Measurements
pyridinoline
51 nmol/mmol creatinine
100 micrograms/kg BID, before, +/- 16.6
pyridinoline
87.1 nmol/mmol creatinine
100 micrograms/kg BID, after, +/- 8.2
p value for Pyridinoline increase with rhIGF-I 100 micrograms/kg BID versus pretreatment
< 0.05 p value
Pyridinoline increase with rhIGF-I 100 micrograms/kg BID versus pretreatment
Source sentences
Summary
There was also a significant (P < 0.05) increase in markers of bone resorption as assessed by PYRX (51.0 +/- 16.6 to 87.1 +/- 8.2 nmol/mmol creatinine) and DPYRX (17.3 +/- 4.5 to 26.3 +/- 3.7 nmol/mmol creatinine).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383006
09HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, high-dose rhIGF-I significantly increased deoxypyridinoline.
In plain wordsIn women with anorexia nervosa, high-dose rhIGF-I increased deoxypyridinoline, a bone resorption marker.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseDeoxypyridinoline
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 micrograms/kg BID · subcutaneous · 6 daysAs given in this study (human).
Measurements
deoxypyridinoline
17.3 nmol/mmol creatinine
100 micrograms/kg BID, before, +/- 4.5
deoxypyridinoline
26.3 nmol/mmol creatinine
100 micrograms/kg BID, after, +/- 3.7
p value for Deoxypyridinoline increase with rhIGF-I 100 micrograms/kg BID versus pretreatment
< 0.05 p value
Deoxypyridinoline increase with rhIGF-I 100 micrograms/kg BID versus pretreatment
Source sentences
Summary
There was also a significant (P < 0.05) increase in markers of bone resorption as assessed by PYRX (51.0 +/- 16.6 to 87.1 +/- 8.2 nmol/mmol creatinine) and DPYRX (17.3 +/- 4.5 to 26.3 +/- 3.7 nmol/mmol creatinine).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383007
10HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, low-dose rhIGF-I significantly increased PICP.
In plain wordsIn women with anorexia nervosa, low-dose rhIGF-I increased PICP, a bone formation marker.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePICP
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 micrograms/kg BID · subcutaneous · 6 daysAs given in this study (human).
Measurements
PICP
110.9 ng/mL
30 micrograms/kg BID, before, +/- 47.0
PICP
134.8 ng/mL
30 micrograms/kg BID, after, +/- 43.2
p value for PICP increase with rhIGF-I 30 micrograms/kg BID versus pretreatment
< 0.05 p value
PICP increase with rhIGF-I 30 micrograms/kg BID versus pretreatment
Source sentences
Summary
The group randomized to receive short term administration of rhIGF-I at a dose of 30 micrograms/kg BID demonstrated a significant (P < 0.05) increase in PICP (110.9 +/- 47.0 to 134.8 +/- 43.2 ng/mL) and an insignificant increase in OC levels (4.5 +/- 3.2 to 6.8 +/- 5.9 ng/mL).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383008
11HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, the osteocalcin increase with low-dose rhIGF-I was not significant.
In plain wordsIn women with anorexia nervosa, the osteocalcin increase with low-dose rhIGF-I was not significant.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeOsteocalcin
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 micrograms/kg BID · subcutaneous · 6 daysAs given in this study (human).
Measurements
Osteocalcin
4.5 ng/mL
30 micrograms/kg BID group, before treatment (4.5 +/- 3.2)
Osteocalcin
6.8 ng/mL
30 micrograms/kg BID group, after treatment (6.8 +/- 5.9)
Source sentences
Summary
The group randomized to receive short term administration of rhIGF-I at a dose of 30 micrograms/kg BID demonstrated a significant (P < 0.05) increase in PICP (110.9 +/- 47.0 to 134.8 +/- 43.2 ng/mL) and an insignificant increase in OC levels (4.5 +/- 3.2 to 6.8 +/- 5.9 ng/mL).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383009
12HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, markers of bone resorption were unchanged with rhIGF-I at 30 micrograms/kg BID.
In plain wordsIn women with anorexia nervosa, markers of bone resorption were unchanged with the lower rhIGF-I dose.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeMarkers of bone resorption
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 micrograms/kg BID · subcutaneous · 6 daysAs given in this study (human).
Source sentences
Summary
At a dose of rhIGF-I of 30 micrograms BID, there was an increase in one marker of bone formation, PICP, without a change in markers of bone resorption.
3 context sentences(design, population, supporting numbers)
Summary · context
Bone turnover was assessed at baseline and after 3 and 6 days of treatment using two markers of bone formation [osteocalcin (OC) and type I procollagen carboxyl-terminal propeptide (PICP)] and three specific markers of bone resorption [pyridinoline (PYRX), deoxypyridinoline (DPYRX), and N-telopeptide (NTX)].
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
Report a problemFND-0892383010

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

13HumanEndogenous levelObservational studyOther
In women with anorexia nervosa, natural IGF-I levels were lower than in age-matched controls.
In plain wordsIn women with anorexia nervosa, natural IGF-I levels were lower than in age-matched controls.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseBaseline IGF-I
Study
n: not reported in source
Comparator
Age-matched controls
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
serum IGF-I
203 ng/mL
women with anorexia nervosa at baseline, +/- 93
serum IGF-I
262 ng/mL
age-matched controls, +/- 84
Source sentences
Summary
IGF-I levels were relatively low at baseline compared to those in age-matched controls (203 +/- 93 vs. 262 +/- 84 ng/mL;P < 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 23 women, aged 18-29 yr (mean +/- SD, 23 +/- 4 yr) with AN.
Summary · context
Patients were randomized to receive rhIGF-I (100 or 30 micrograms/kg) or placebo sc twice a day for 6 days.
This result measures the body's own IGF-1 (mecasermin). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0892383001

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.